

## AMENDMENTS TO THE SPECIFICATION

Beginning on a new page immediately before the claims, please replace the existing sequence listing with the attached substitute sequence listing. Please renumber subsequent pages accordingly.

Please replace the paragraph [0184] on page 57 with the following amended paragraph:

[0184] Table 5: Sequences of *Cis*-repressive RNA Sequences, Loop, RBS, and crRNA Constructs. All sequences are shown 5' to 3' and represented in the form of their corresponding DNA sequences as used in the cloning steps.

<i>Cis</i> -Repressive Sequence	Sequence ID NO:
C GGACGCACTGACCGAATT	SEQ ID NO: 3
crRL CTACCTTCTCCTCTTAAAT	SEQ ID NO: 4
crRB TTCTCTAGTCCTCCTTAT	SEQ ID NO: 5
crR7 CTACCTTCTCCTCTAGGA	SEQ ID NO: 6
crR10 CTACCTATCTGCTCTGAA	SEQ ID NO: 7
crR12 CTACCATTCACCTCTTGGAA	SEQ ID NO: 8
crR22 CTACCATTCACCTGGAA	SEQ ID NO: 9
Loop TTTGGGT	SEQ ID NO: 10
RBS ATTAAAGAGGAGAAA	SEQ ID NO: [[11]] 10
Sequence of <i>Cis</i> -Repressive RNA Constructs	
C GGACGCACTGACCGAATTCA TTAAAGAGGAGAAA GGTACCATG	SEQ ID NO: [[12]] 11
crRL CTACCTTCTCCTCTTAAATT TTGGTATTAAAGAG GAGAAAGGTACCATG	SEQ ID NO: [[13]] 12
crRB CTCTAGTCCTCCTTATT TTGGTATTAAAGAGGAG AAAGGTACCATG	SEQ ID NO: [[14]] 13
crR7 CTACCTTCTCCTCTAGGATT TTGGTATTAAAGAG GAGAAAGGTACCATG	SEQ ID NO: [[15]] 14
crR10 CTACCTATCTGCTCTGAA ATTGGTATTAAAGAG GAGAAAGGTACCATG	SEQ ID NO: [[16]] 15
crR12 CTACCATTCACCTCTGGATT GGTATTAAAGAG GAGAAAGGTACCATG	SEQ ID NO: [[17]] 16
<del>er22</del> <u>crR22</u> CTACCATTCACCTCTGGATT GGTATTAAAGAG GAGAAAGGTACCATG	SEQ ID NO: [[18]] 17

Please replace the paragraph [0194] on page 60 with the following amended paragraph:

[0194] Table 6: Sequences of *Trans*-activating RNA Constructs. 5'-st represents the 5' stabilizer element inserted in front of taR12. All sequences are shown 5' to 3' and represented in the form of their corresponding DNA sequences as used in the cloning steps.

Construct/Sequence	Sequence ID NO
taRL ACACCCAAATTAAAGAGGAGAAAGGTAGTGGTGGTTAATGAAA- ATTAACCTACTACTACCTTTCTTAGA	SEQ ID NO: [[19]] <u>18</u>
taRB ACGCCCAATAAGGAGGGATAGAGTGGTGGTTAATGAAAATTAAC- TTACTACTTAGTTCTAGA	SEQ ID NO: [[20]] <u>19</u>
taR7 ACACCCAAATCCTAGGGAGAATGGTAGTGGTGGTTAATGAAAAT- TTAACCTACTACTACCTTTCTAGA	SEQ ID NO: [[21]] <u>20</u>
taR10 ACACCCAAATTATGAGCAGATTGGTAGTGGTGGTTAATGAAAAT- TTAACCTACTACTACCTTTCTAGA	SEQ ID NO: [[22]] <u>21</u>
taR12 ACCCAAATCCAGGAGGTGATTGGTAGTGGTGGTTAATGAAAAT- TAACCTACTACTACCATATATCTCTAGA	SEQ ID NO: [[23]] <u>22</u>
taR12A ACCCAAATCCAGGAGGTGAATGGTAGTGGTGGTTAATGAAAAT- TAACCTACTACTACCATATATCTCTAGA	SEQ ID NO: [[24]] <u>23</u>
taR12B ACCCAAATCCAAGAGGTGATTGGTAGTGGTGGTTAATGAAAAT- TAACCTACTACTACCATATATCTCTAGA	SEQ ID NO: [[25]] <u>24</u>
taR12C ACCCAAATCCAAGAGGTGAATGGTAGTGGTGGTTAATGAAAAT- AATTAACTTACTACTACCATATATTCTCTAGA	SEQ ID NO: [[26]] <u>25</u>
taRU112 ACCCAAATCCAGGAGGTGATTGGTAGTGGTGGTTAATGAAAAT- TAACCTACTAAAATCGGACATCTCTAGA	SEQ ID NO: [[27]] <u>26</u>
taRU212 ACCCAAATCCAGGAGGTGATTGGTAGTGGTGGTTAATGAAAAT- TAACCTTACTACTACCGCGTCATATCTCTAGA	SEQ ID NO: [[28]] <u>27</u>
taRU312 ACCCAAATCCAGGAGGTGATTGGTAGTGGTGGTTAATGAAAAT- TAACCTTACTACGATCAGTGATCTCTAGA	SEQ ID NO: [[29]] <u>28</u>
taR22 ACCCAAATCCAGGTGTATGGTAGTGGTGGTTAATGAAAATTAAC- TTACTACCATTACCTCGATCTAGA	SEQ ID NO: [[30]] <u>29</u>
5'-st GGGUCCGCUAUGAGGUAAAGUGUCAUAGCGGGCCC	SEQ ID NO: [[31]] <u>30</u>

Please replace the paragraph [0199] on page 61 with the following amended paragraph:

[0199] Step 2: Complex formation. For each of the riboregulator pairs, six samples with different molar ratios of taRNA-crRNA were prepared. The concentrations of taRNA in the six samples were: 1.0  $\mu$ M, 0.50  $\mu$ M, 0.25  $\mu$ M, 0.13  $\mu$ M, 0.06  $\mu$ M, and 0.03  $\mu$ M. The concentrations of crRNA were 0.20  $\mu$ M and 0.01  $\mu$ M for cognate (e.g., taR12-crR12) and non-cognate (e.g., taR10-crR12) pairs, respectively. Each of the samples contained 10  $\mu$ M Tris (pH=7), 10

$\mu$ M MgCl<sub>2</sub>, 1 pM KCl, 1U of RNase inhibitor (Applied BioSystems), and 0.4 pM of Cy5-labeled reverse transcription primer (5'-Cy5-CTTCACCCTCTCCACTGAC-3') (SEQ ID NO: [[32]] 31). The reverse transcription primer was designed to anneal the crRNA approximately 80 nucleotides downstream of the *gfpmut3b* start codon and contained the Cy-5 label at the 5' end. The samples were given 20 minutes to equilibrate at 37°C.

Please replace the paragraph [0209] on page 64 with the following amended paragraph:

[0209] Table 7: Real-competitive PCR Assay Design.

Assay: 16SrRNA	PCR Primer 1: 5'-ACGTTGGATGGGAGACTGCCAGTGATAAAC (SEQ ID NO: [[33]] 32) PCR Primer 2: 5'-ACGTTGGATGTGTAGCCCTGGTCGTAAGG (SEQ ID NO: [[34]] 33) Extension Primer: 5'-GAGGAAGGTGGGGATGACGT (SEQ ID NO: [[36]] 34) Terminator Mix: CGT Competitor Seq: 5'-TGTAGCCCTGGTCGTAAGGGCCATGATG- ACTTCACGTCATCCCCACCTTCCTCCAG- TTTATCACTGGCAGTCTCC (SEQ ID NO: [[37]] 35)
Assay: crRNA	PCR Primer 1: 5'-ACGTTGGATGGGAGAGGGTGAAGGTGATGC (SEQ ID NO: [[38]] 36) PCR Primer 2: 5'-ACGTTGGAAGAGGTAGTTTCCAGTAGTGC (SEQ ID NO: [[39]] 37) Extension Primer: 5'-CATACGGAAAACCTTACCCCTT (SEQ ID NO: [[40]] 38) Terminator Mix: ACT Competitor Seq: 5'-TGTAGCCCTGGTCGTAAGGGCCATGATGAC- TTCACGTCATCCCCACCTTCCTCCAGTTAT- CACTGGCAGTCTCC (SEQ ID NO: [[41]] 39)
Assay: taRNA	PCR Primer 1: 5'-ACGTTGGATGTTCTCCATAGTCGACACCC (SEQ ID NO: [[42]] 40) PCR Primer 2: 5'-ACGTTGGATGCTGCCGCCAGGCATCTAGAG (SEQ ID NO: [[43]] 41) Extension Primer: 5'-GAAAATTAACTTACTACTACC (SEQ ID NO: [[44]] 42) Terminator Mix: CGT Competitor Seq: Plasmid construct taR 12 (for taR L,10) or Plasmid construct taRL (for taR 12)

Please replace the paragraph [0211] on page 65 with the following amended paragraph:

[0211] T7 = 5'-TAATACGACTCACTATAGG-3' (SEQ ID NO: [[45]] 43). The same set of primers could be used for all crRNA variants because they all contained the same 5' and 3' ends. Due to variable 5' sequences on the taRNA constructs, unique primers were designed for each PCR amplification. The same reverse primer was used in taRNA PCR reactions.

Construct	PCR Primer (forward)
crR7, 10, 12	5'-ATTACTCGAG-T7-TCAGCAGGACGCAGTGC (SEQ ID NO: [[46]] 44)
taR7	5'-ATTACTCGAG-T7-ACCCAAATCCTAGCGGAG (SEQ ID NO: [[47]] <u>45</u> )
taR10	5'-ATTACTCGAG-T7-ACCCAAATTGAGCAGATTG (SEQ ID NO: [[48]] 46)
taR12	5'-ATTACTCGAG-T7-ACCCAAATCCAGGAGGTG (SEQ ID NO: [[49]] 47)

  

Construct	PCR Primer (reverse)
crR7, 10, 12	5'-GTCCAAGCTTTATTTGTATAGTTCATCCA (SEQ ID NO: [[50]] 48)
taR7	
taR10	5'-ACCACCGCGCTACTG (SEQ ID NO: [[51]] <u>49</u> )
taR12	